Determination of <scp>CD43</scp> and <scp>CD200</scp> surface expression improves accuracy of B‐cell lymphoma immunophenotyping

Joerg Hoffmann(Philipps University of Marburg), Cornelia Brendel(Philipps University of Marburg), Michael C. Thrun(Philipps University of Marburg), Andreas Neubauer(RWTH Aachen University), Ute Meissauer(Philipps University of Marburg), Christian Wilhelm(Philipps University of Marburg), Ute Niebergall(Philipps University of Marburg), Ulrich Kaiser(University of Applied Sciences Landshut), Andrea Gruen(Philipps University of Marburg), Marissa Rother(Philipps University of Marburg)
Cytometry Part B Clinical Cytometry
July 27, 2020
10.1002/cyto.b.21936
Cited by 29

Related Papers

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial
|The Lancet|2013|1.5k
Diverse Applications of Nanomedicine
|ACS Nano|2017|1.4k
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k
Immunochemotherapy With Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Significantly Improves Response and Time to Treatment Failure, But Not Long-Term Outcome in Patients With Previously Untreated Mantle Cell Lymphoma: Results of a Prospective Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG)
|Journal of Clinical Oncology|2005|573
Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1–2 study
|The Lancet Oncology|2017|493